Flow, a London, UK-based medical device company focused on treatment of depression, raised $1.5M in funding.
The round was led by Khosla Ventures.
The company intends to use the funds for the European rollout and introduction to healthcare clinics, and the conduction of clinical studies.
Led by Daniel Mansson, Flow is a physical and behavioural, at-home treatment for depression which comprises a portable brain stimulation headset and therapy app. It combines clinical psychology, neuroscience and innovative technology including machine learning. The headset uses transcranial direct current stimulation (tDCS), a form of neurostimulation that delivers constant, low direct current via electrodes on the head to stimulate and rebalance neural activity in this area.
The brain stimulation headset is used in combination with a therapy app. This educates users with videos about depression and advice on how to reduce symptoms using the latest expert knowledge from the fields of sleep, nutrition, fitness and meditation.
Classified as a Class IIa medical device, Flow launched in June 2019 in the UK and Sweden.
The Flow headset retails at £399. The app, available on iOS, is free.